Tagged with regulation,

regulation The general manager of Algeria’s pharmaceuticals regulator narrates the founding and evolution of the institution, how it has been flexing its muscles with the withdrawal of no less than 17 products from the local market, and how the body has been selected to play a leading role in the WHO’s Expert Advisory Panel on…

IP Alicia Alvarez Berkenwald, Partner at the specialized intellectual property services firm Berken IP, gives an introduction to the Argentinian IP environment, common strategies used to bypass obstacles, and Berken IP’s role in helping increase IP awareness in Argentinian research institutions.   Could you give us an overview of the changes…

Novo Nordisk The global COO of the multinational at the forefront of the fight against diabetes explains why the Algerian market is so strategically important and how the ‘made in Algeria’ brand would have real potential at the regional level if only the government would remove impediments to export. As COO of Novo…

doing business Insights from existing players on what to expect and how to succeed in Algeria today. “The key to being successful is to be direct and forthright with the Algerians themselves. Trust in them and they will certainly trust in you.” – Essam Farouk, CEO, El Kendi. “The pace of doing…

CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research.   What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…

Boston Consulting Group The managing director of Boston Consulting Group Malaysia discusses the gap between public and private healthcare in the country, and what can be done to bridge it.   What appears to be a focus for many companies now is bridging the gap between the private healthcare sector and the public…

pricing Cho Chan-Hwui, president of the Korean Pharmaceutical Association (KPA), discusses the major hurdles that pharmacists in Korea must overcome today, and the increased focus on prescription by INN.   How successfully has the policy stipulating the separation of prescription and dispensing (SPD) worked over the last 15 years? Complete success…

innovation Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of the world for disruptive and incremental innovation.   What are the current trends in Korea’s pharmaceutical industry? The global market…

advisory Nicola Carusoni, PwC’s lead pharmaceutical partner in Buenos Aires, gives an overview of the key trends in the Argentinian pharma industry and discusses the importance of PwC as a partner to the industry given the current economic context.   What are the key trends in the Argentinian pharmaceutical market at present? The…

doing business Montse Planas was appointed as General Manager of Fresenius Kabi Spain just as the financial crisis went into a downward spin. Today she discusses the efforts the company made to respond to the crisis, and ways in which cost-cutting could be implemented in Spain.   What were some of the…